Actinium Pharmaceuticals (NYSE:ATNM) Rating Increased to Hold at StockNews.com

StockNews.com upgraded shares of Actinium Pharmaceuticals (NYSE:ATNM) from a sell rating to a hold rating in a research note released on Wednesday.

Separately, HC Wainwright reissued a “buy” rating and issued a $4.00 target price on shares of Actinium Pharmaceuticals in a report on Tuesday. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $7.40.

Actinium Pharmaceuticals Price Performance

NYSE:ATNM opened at $1.29 on Wednesday. Actinium Pharmaceuticals has a 12 month low of $1.03 and a 12 month high of $10.24. The firm has a market capitalization of $40.24 million, a PE ratio of -0.93 and a beta of -0.27. The business’s fifty day moving average price is $1.27 and its 200 day moving average price is $1.44.

Hedge Funds Weigh In On Actinium Pharmaceuticals

Several institutional investors have recently bought and sold shares of ATNM. Wellington Management Group LLP purchased a new stake in Actinium Pharmaceuticals in the 3rd quarter valued at approximately $112,000. Geode Capital Management LLC grew its holdings in shares of Actinium Pharmaceuticals by 3.0% in the 3rd quarter. Geode Capital Management LLC now owns 686,153 shares of the company’s stock worth $1,290,000 after acquiring an additional 19,843 shares during the period. Barclays PLC raised its holdings in Actinium Pharmaceuticals by 323.0% during the third quarter. Barclays PLC now owns 42,935 shares of the company’s stock worth $81,000 after purchasing an additional 32,784 shares during the last quarter. Vontobel Holding Ltd. purchased a new position in shares of Actinium Pharmaceuticals in the fourth quarter valued at $32,000. Finally, Los Angeles Capital Management LLC lifted its holdings in shares of Actinium Pharmaceuticals by 25.0% in the fourth quarter. Los Angeles Capital Management LLC now owns 213,950 shares of the company’s stock valued at $270,000 after purchasing an additional 42,770 shares in the last quarter. 27.50% of the stock is owned by institutional investors and hedge funds.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).